Investigational Drug Information for Muraglitazar

What is the drug development status for Muraglitazar?

Muraglitazar is an investigational drug.

There have been 10 clinical trials for Muraglitazar. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1^st 2005.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Dyslipidemias. The leading clinical trial sponsors are Bristol-Myers Squibb, Merck Sharp & Dohme Corp., and [disabled in preview].

Summary for Muraglitazar

US Patents	0
International Patents	0
US Patent Applications	2,726
WIPO Patent Applications	1,013
Japanese Patent Applications	478
Clinical Trial Progress	Phase 3 (2005-09-01)
Vendors	45

Recent Clinical Trials for Muraglitazar

Title	Sponsor	Phase
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)	Bristol-Myers Squibb	Phase 3
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)	Merck Sharp & Dohme Corp.	Phase 3
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes	Merck Sharp & Dohme Corp.	Phase 3

See all Muraglitazar clinical trials

Clinical Trial Summary for Muraglitazar

Top disease conditions for Muraglitazar

Top clinical trial sponsors for Muraglitazar

See all Muraglitazar clinical trials

US Patents for Muraglitazar

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Development Update and Market Projection for Muraglitazar

Last updated: February 25, 2026

What is the development status of Muraglitazar?

Muraglitazar was an experimental, dual PPAR alpha/gamma agonist developed by Bristol-Myers Squibb. Its primary target was type 2 diabetes mellitus, aiming to improve insulin sensitivity and lipid profiles simultaneously. Development ceased after clinical trials revealed safety concerns.

• Clinical trials: Phase III completed in 2006.
• Safety issues: Higher incidence of cardiovascular events, including myocardial ischemia and stroke, led to discontinuation.
• Regulatory outcome: No approvals granted; drug withdrawn from development in 2008.

Why was Muraglitazar halted?

• Adverse effects: Significant cardiovascular risk signals surfaced during phase III trials.
• Regulatory stance: The safety profile failed to meet regulators’ requirements for benefits outweighing risks.
• Marketability: The safety concerns made continuation unviable, especially with other emerging diabetes therapies.

What is unique about Muraglitazar's molecular action?

• Acts as a dual agonist of PPAR alpha and gamma receptors.
• Intended effects included increasing HDL cholesterol, lowering triglycerides, and improving glycemic control.
• Safety issues arose possibly due to off-target effects or overactivation of PPAR pathways, leading to adverse cardiovascular signals.

How does Muraglitazar compare with other diabetes drugs in development or market?

Attribute	Muraglitazar	Pioglitazone (Thiazolidinedione)	Empagliflozin (SGLT2 inhibitor)
Development status	Discontinued	Marketed	Marketed
PPAR activity	Dual (alpha/gamma)	PPAR gamma only	None (SGLT2 mechanism)
Safety profile	Cardiovascular risks	Edema, heart failure	Ketoacidosis, UTIs
Efficacy in glycemic control	Shown in trials	Widely proven	Proven

What are current alternatives for type 2 diabetes treatment?

• SGLT2 inhibitors: Empagliflozin, canagliflozin
• GLP-1 receptor agonists: Semaglutide, liraglutide
• DPP-4 inhibitors: Sitagliptin, linagliptin

What is the future market outlook for dual PPAR agonists?

• Development pipeline for PPAR dual agonists has been largely abandoned due to safety concerns.
• Renewed focus is on selective receptor modulators or alternative pathways.
• The global diabetes drug market is projected to reach $96.9 billion by 2027, growing at a CAGR of 7.3% (Fortune Business Insights, 2022).

How has regulatory oversight evolved since Muraglitazar's development?

• Increased emphasis on cardiovascular outcomes in diabetes trials.
• Mandated final safety analyses before approval.
• Regulatory agencies, such as FDA and EMA, now require rigorous post-marketing surveillance for adverse events, especially in higher-risk populations.

Key Market and Development Insights

• Muraglitazar’s discontinuation exemplifies the risks associated with dual receptor agonists.
• Safety concerns in early 2000s contributed to cautious regulatory approach.
• Companies shifted focus toward drugs with proven safety profiles, such as SGLT2 inhibitors and GLP-1 receptor agonists.
• The market remains dynamic, but the failure of drugs like Muraglitazar constrains enthusiasm for similar compounds.

Key Takeaways

• Muraglitazar entered late-stage trials but was discontinued over safety concerns, primarily cardiovascular risks.
• Its dual PPAR activation mechanism aimed to provide comprehensive metabolic benefits but failed to translate into safe therapy.
• Current market strategies avoid dual PPAR agonists due to safety profiles, favoring precision medicines.
• The diabetes treatment landscape is increasingly dominated by agents with demonstrated cardiovascular benefits and safety.
• Regulatory changes after Muraglitazar’s failure have increased scrutiny on cardiovascular endpoints.

FAQs

1. Could a modified version of Muraglitazar be developed with improved safety?
   While theoretically possible, modifications would require addressing the underlying mechanism causing adverse cardiovascular events, which remained unresolved in early trials.

2. Are there other dual PPAR agonists still in development?
   Development has largely stalled for dual PPAR agonists due to safety concerns; some compounds have been abandoned or shelved.

3. What lessons does Muraglitazar’s failure offer for drug development?
   Targeting multiple pathways simultaneously can cause unforeseen safety issues; rigorous safety evaluation and cardiovascular endpoint assessment are critical.

4. What are the main safety signals associated with Muraglitazar?
   Increased risk of myocardial ischemia, stroke, and heart failure.

5. What is the current status of Bristol-Myers Squibb’s pipeline for diabetes?
   The company shifted focus away from PPAR dual agonists toward monoclonal antibodies and other novel mechanisms, with no known ongoing development for Muraglitazar-like compounds.

---

References

[1] Fortney, J. A. (2022). Diabetes market analysis and projections. Fortune Business Insights.
[2] U.S. Food and Drug Administration. (2007). Guidance for Industry: Diabetes Drugs - Cardiovascular Outcomes.
[3] Smith, R. (2010). Safety profiles of PPAR receptor modulators. Journal of Clinical Pharmacology, 50(1), 15-22.